
News from CureDuchenne
We’ve assigned a rating of Unknown factuality to CureDuchenne. You can read more about how we’ve determined CureDuchenne’s credibility and reliability as a news source here: https://groundnews.lakegeneva.lib.wi.us/rating-system.
Media Bias Ratings
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top CureDuchenne News

United States · United StatesCapricor Therapeutics said on Tuesday the U.S. Food and Drug Administration may not seek its outside experts' advice when deciding on the company's cell therapy for a heart condition associated with Duchenne muscular dystrophy.See the Story
Capricor says FDA may not convene expert panel for cell therapy
100% Left coverage: 1 sources

United States · United StatesWATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $250.8 million of shares of its common stock and, in lieu of common stock to […] The post Kymera Therapeutics Announces Pricing of $250 Million Public Off…See the Story
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
100% Left coverage: 1 sources
PepGen to discontinue development of experimental Duchenne therapy; shares drop
100% Center coverage: 1 sources
Satellos’ DMD treatment shows efficacy signals in adult patients
CureDuchenne Ventures Invests in Entos Pharmaceuticals
CureDuchenne Appoints Brenda Wong, MD, as Chief Medical Advisor to Advance Research and Improve Care for Individuals with Duchenne and Becker
100% Center coverage: 3 sources